David Amsellem: Hey, thanks. So I just had a couple of product-specific questions. Can you talk through how you’re thinking about the long-term sustainability of Unithroid growth, I know there’s some unique features regarding the levothyroxine market. So what’s your level of confidence you continue to grow that business just significantly just beyond not only 2023, but beyond 2023. That’s number one. Number two, Adrenaclick with a number of different formulations of epinephrine that are in development? Do you think that could be disruptive to Adrenaclick over the long-term? In other words, the injectable formulations? And then lastly, maybe another question on IPX-203. Do you envision most Rytary patients switching over? And do you — or do you vision overall market expansion. What’s the right way to think about the opportunity there vis-a-vis switching versus market expansion? Thank you.
Chirag Patel: Thank you, David and good morning. So let’s say — Unithroid is, you know, there are multiple generics products in the market and patients do not like to — some of the patients have a hard time switching over in their use to Unithroid and they’re continuing on Unithroid. It’s a very small market share, like 0.05, you know, how large market is it. We believe that study keeps growing and the more and more patients and providers and physicians want that patient to be on a consistent drug rather than switching over and subject to be switching over to multiple generics products. Adrenaclick, we have a new nasal spray for sports through Unithroid, it’s even gets approved for mothers — parents to have use it not to have the with it, it’s kind of not possible.
It will take time. They have not done any clinical. So I bet knowing parents will be my softening a parent, I will not take that chance and just in nasal spray versus epiband Adrenaclick, maybe carry both for a while. So we see — even if it brings any penetration. It will be over time, and it will be a slower penetration. And we have to see the pricing dynamic. Are they going to be competitive to Adrenaclick. And that’s another one. IPX-203, Rytary, we expect over time, half of the patients would move over to IPX-203, it is a better product, obviously. And going on for the broader market, as I have mentioned earlier, much broader market, there are 3 million prescriptions for CDLD, so we have for Rytary 150,000 only. So we’re going to grow the business into a 5% penetration, try to go for pretty much converting as many as we can.
And our pricing strategy is so unique and awesome, which we well received that we believe the coverage will be much bigger for both medicare and commercial patients, really excited on IPX-203.
Operator: Our next question is from Balaji Prasad from Barclays. Balaji, your line is now open. Please go ahead.
Balaji Prasad: Good morning,
Anthony DiMeo: Balaji, your — there’s some interference on your line, Balaji. I don’t know if there is anything you could do about that?
Tasos Konidaris: Hey, Balaji. We kind of lost you a little bit. Do you mind if you can come across very clear. So do you mind if you repeat your question, please?
Balaji Prasad: Absolutely. Got it. So couple of questions for me. Firstly on IPX-203, Chirag you mentioned that it doesn’t see much kind of information with this product. We just kind of where the market seems to model
Anthony DiMeo: Sorry, Balaji, this is Tony. It’s still hard to hear you. Happy to follow-up with you perhaps after the call.
Tasos Konidaris: Or even Balaji, maybe you can e-mail the question over to Tony, if you can e-mail in the question. And if we get it in time, Tony can address it on the call and we will give you an answer. Is that okay?
